Literature DB >> 8262637

Effect of lipopolysaccharide (LPS) chain length on interactions of bactericidal/permeability-increasing protein and its bioactive 23-kilodalton NH2-terminal fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli.

C Capodici1, S Chen, Z Sidorczyk, P Elsbach, J Weiss.   

Abstract

The target-specific cytotoxicity for gram-negative bacteria and the endotoxin-neutralizing activity of the 55-kDa bactericidal/Permeability-increasing protein (BPI) and its bioactive 23-kDa NH2-terminal fragment depend on the strong attraction of BPI for the lipid A region of lipopolysaccharides (LPS). We have shown before that smooth gram-negative bacteria with long-chain LPS are more resistant to BPI (especially holo-BPI) than are rough strains. It has been suggested that the high BPI resistance of some gram-negative bacteria, such as Proteus mirabilis, might also reflect the structural diversity of lipid A. To explore this possibility, we compared the antibacterial activity and binding of natural and recombinant holo-BPI and a recombinant NH2-terminal fragment (rBPI-23) to an isogenic rough (Re-LPS chemotype) and a smooth (S-LPS chemotype) strain of P. mirabilis and to LPS isolated from the two strains. Holo-BPI and rBPI-23 were both potently active against the Re strain of P. mirabilis (90% lethal dose, 20 nM). In contrast, the smooth strain was > or = 100 times more resistant to holo-BPI but only 10 times more resistant to rBPI-23. rBPI-23 was also more potent against several Escherichia coli strains from clinical bacteremia isolates. Differences in the antibacterial potency of BPI toward the Re and S strains of P. mirabilis correlated with differences in the binding of holo-BPI and rBPI-23 to these bacteria. In contrast, the binding of biosynthetically (in vitro transcribed and translated) 35S-labeled holo-BPI and NH2-terminal fragment to isolated Re- and S-LPS from P. mirabilis in solution was similar. Moreover, in the Limulus amebocyte lysate assay, holo-BPI and rBPI-23 potently neutralized both forms of LPS with equal effectiveness. Together, these results strongly suggest that BPI recognizes Proteus lipid A and that the relative resistance of (smooth) P. mirabilis to holo-BPI is due to the inhibitory effect of long polysaccharide chains of tightly packed LPS in the envelope.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8262637      PMCID: PMC186095          DOI: 10.1128/iai.62.1.259-265.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Bidirectional movement of a nascent polypeptide across microsomal membranes reveals requirements for vectorial translocation of proteins.

Authors:  C E Ooi; J Weiss
Journal:  Cell       Date:  1992-10-02       Impact factor: 41.582

2.  The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin.

Authors:  M N Marra; C G Wilde; M S Collins; J L Snable; M B Thornton; R W Scott
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

3.  Serum resistance in Escherichia coli strains causing acute pyelonephritis and bacteraemia.

Authors:  S H Jacobson; C G Ostenson; K Tullus; A Brauner
Journal:  APMIS       Date:  1992-02       Impact factor: 3.205

4.  Molecular modelling of the three-dimensional structure and conformational flexibility of bacterial lipopolysaccharide.

Authors:  M Kastowsky; T Gutberlet; H Bradaczek
Journal:  J Bacteriol       Date:  1992-07       Impact factor: 3.490

5.  Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria.

Authors:  J Weiss; P Elsbach; C Shu; J Castillo; L Grinna; A Horwitz; G Theofan
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Comparison of granule proteins from human polymorphonuclear leukocytes which are bactericidal toward Pseudomonas aeruginosa.

Authors:  K R Wasiluk; K M Skubitz; B H Gray
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

7.  Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides.

Authors:  J B Parent; H Gazzano-Santoro; D M Wood; E Lim; P T Pruyne; P W Trown; P J Conlon
Journal:  Circ Shock       Date:  1992-09

8.  Reactivity of monoclonal antibody E5 with endotoxin. I. Binding to lipid A and rough lipopolysaccharides.

Authors:  D M Wood; J B Parent; H Gazzano-Santoro; E Lim; P T Pruyne; J M Watkins; E S Spoor; D T Reardan; P W Trown; P J Conlon
Journal:  Circ Shock       Date:  1992-09

9.  High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide.

Authors:  H Gazzano-Santoro; J B Parent; L Grinna; A Horwitz; T Parsons; G Theofan; P Elsbach; J Weiss; P J Conlon
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

10.  Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils.

Authors:  C E Ooi; J Weiss; M E Doerfler; P Elsbach
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  25 in total

Review 1.  A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Authors:  O Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Antimicrobial activity of PLUNC protects against Pseudomonas aeruginosa infection.

Authors:  Lina Lukinskiene; Yang Liu; Susan D Reynolds; Chad Steele; Barry R Stripp; George D Leikauf; Jay K Kolls; Y Peter Di
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

3.  Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides.

Authors:  Miguel A Campos; Miguel A Vargas; Verónica Regueiro; Catalina M Llompart; Sebastián Albertí; José A Bengoechea
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

4.  Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms.

Authors:  Lutz Hamann; Christian Alexander; Cordula Stamme; Ulrich Zähringer; Ralf R Schumann
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.

Authors:  C Urban; N Mariano; J J Rahal; E Tay; C Ponio; T Koprivnjak; J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 6.  Bacteria in the intestine, helpful residents or enemies from within?

Authors:  Geraldine O Canny; Beth A McCormick
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

7.  Molecular dynamics simulations of six different fully hydrated monomeric conformers of Escherichia coli re-lipopolysaccharide in the presence and absence of Ca2+.

Authors:  S Obst; M Kastowsky; H Bradaczek
Journal:  Biophys J       Date:  1997-03       Impact factor: 4.033

8.  rBPI(21) promotes lipopolysaccharide aggregation and exerts its antimicrobial effects by (hemi)fusion of PG-containing membranes.

Authors:  Marco M Domingues; Miguel A R B Castanho; Nuno C Santos
Journal:  PLoS One       Date:  2009-12-22       Impact factor: 3.240

9.  Alternative sigma factor RpoE is important for Vibrio parahaemolyticus cell envelope stress response and intestinal colonization.

Authors:  Brandy Haines-Menges; W Brian Whitaker; E Fidelma Boyd
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

10.  Fold-unfold transitions in the selectivity and mechanism of action of the N-terminal fragment of the bactericidal/permeability-increasing protein (rBPI(21)).

Authors:  Marco M Domingues; Sílvia C D N Lopes; Nuno C Santos; Alexandre Quintas; Miguel A R B Castanho
Journal:  Biophys J       Date:  2009-02       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.